Cannabinol Shows Mixed Results for Insomnia in First Rigorous Clinical Trial | Research

The takeaway

Cannabinol didn't significantly reduce nighttime wakefulness but the higher dose improved subjective sleep quality, shortened time to fall asleep, and reduced brain arousal markers.

Sleep medicine specialists, CBN product consumers, cannabis medicine researchers, regulatory scientists

What the researchers found

300 mg CBN did not significantly change the primary outcome (WASO: -6.3 min, p=0.29) but improved subjective sleep quality (p=0.005), reduced sleep onset latency (p=0.004), increased N2 sleep (p=0.03), and reduced EEG arousal indices (p=0.02). The 30 mg dose showed no significant effects.

Why it matters

CBN is heavily marketed as a sleep aid despite virtually no clinical evidence. This first rigorous trial shows it has some real effects on sleep architecture and subjective quality, but doesn't meet the primary bar of reducing nighttime wakefulness.

The numbers in context

20 participants. 300 mg CBN: WASO -6.3 min (NS), sleep onset latency improved (p=0.004, dz=-0.74), N2 sleep increased (p=0.03, dz=0.54), subjective quality improved (p=0.005, dz=0.56), arousal index reduced (p=0.02, dz=-0.65). 247 mild-moderate adverse events across all arms.

How the study worked

Randomized, double-blind, placebo-controlled, three-arm, single-night crossover trial in 20 adults with physician-diagnosed insomnia disorder (ISI ≥15). Participants received single doses of 30 mg CBN, 300 mg CBN, or placebo with 2-week washout, measured by overnight polysomnography.

What this study cannot tell us

Very small sample (20 participants). Single-night assessment doesn't capture effects of repeated use. 17 of 20 participants were female, limiting generalizability. High adverse event count across all arms. 300 mg is a very high dose rarely found in consumer products.

How to read the evidence

Gold-standard RCT design with polysomnography provides reliable data, but very small sample and single-night dosing limit definitive conclusions.

When this study was published

Published 2026, conducted 2022-2023. First placebo-controlled PSG trial of CBN for diagnosed insomnia.

The bigger picture

The CBN sleep market is booming based on anecdote and marketing. This trial provides the first objective evidence — and the picture is more nuanced than industry claims suggest. CBN may help some aspects of sleep without being a cure-all for insomnia.

Questions still open

Would multi-night dosing show cumulative benefits? Why did the primary outcome (WASO) fail while secondary outcomes succeeded? Could lower doses between 30-300 mg find a therapeutic sweet spot? Are the 247 adverse events clinically meaningful?

Common questions

Does CBN actually help you sleep?

The first rigorous clinical trial found mixed results: 300 mg CBN didn't significantly reduce nighttime wakefulness (the primary measure), but it did help people fall asleep faster, improved subjective sleep quality, and reduced brain arousal markers.

How much CBN do you need for sleep effects?

In this trial, 30 mg showed no significant effects, while 300 mg showed several improvements — but 300 mg is far higher than what most consumer products contain, raising questions about whether typical CBN products provide enough.

Read the original research

Cannabinol for Acute Treatment of Insomnia Disorder in a Randomized Placebo-Controlled Crossover Trial.

Journal of sleep research, e70284

View on PubMed ↗Publisher’s paper ↗

Citation

Lavender, Isobel G; Marshall, Nathaniel S; McCartney, Danielle; Cho, Garry; Irwin, Chris; Suraev, Anastasia; Gordon, Rebecca; Arnold, Jonathon C; D'Rozario, Angela L; Gordon, Christopher J; Saini, Bandana; Sivam, Sheila; Zheng, Yizhong; Grunstein, Ronald R; Yee, Brendon J; McGregor, Iain S; Hoyos, Camilla M. (2026). Cannabinol for Acute Treatment of Insomnia Disorder in a Randomized Placebo-Controlled Crossover Trial.. Journal of sleep research, e70284. https://doi.org/10.1111/jsr.70284